HSCS

HeartSciences Inc. operates as a medical technology company focused on developing artificial intelligence-powered diagnostic solutions for cardiovascular disease. Headquartered in Southlake, Texas, the company specializes in electrocardiogram (ECG) analysis technology designed to improve the early detection of heart conditions. Its flagship product, MyoVista, is a resting 12-lead ECG device that utilizes advanced signal processing and machine learning algorithms to identify cardiac abnormalities that traditional ECG systems may miss. The technology analyzes subtle waveform changes to detect myocardial dysfunction and other cardiac irregularities, positioning the company in the growing market for AI-enhanced cardiac diagnostics. HeartSciences markets MyoVista primarily to healthcare providers, including hospitals, clinics, and physician offices, targeting improved patient outcomes through earlier intervention. The company received FDA 510(k) clearance for MyoVista and holds CE Mark certification for European markets. As a clinical-stage medical device company, HeartSciences continues to pursue additional clinical validation studies and regulatory pathways to expand its product's diagnostic capabilities and market reach. The company operates with a lean organizational structure focused on product development, clinical research, and commercialization activities. HeartSciences trades on the NASDAQ under the ticker symbol HSCS and remains in the growth phase of building market adoption for its cardiovascular diagnostic platform.